Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity in human pancreatic cancer cells.

CONCLUSION: Our findings demonstrated that IL-6 stimulates pancreatic cancer cell proliferation, survival and glycolysis, and supported persistent IL-6 signaling is a viable therapeutic target for pancreatic cancer using IL-6/GP130 inhibitors. PMID: 29714141 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29714141?dopt=Abstract

Source: Current Cancer Drug Targets - April 30, 2018 Category: Cancer & Oncology Authors: Chen X, Tian J, Su GH, Lin J Tags: Curr Cancer Drug Targets Source Type: research